Nicholas Conrad Smith - Feb 1, 2024 Form 3 Insider Report for Alto Neuroscience, Inc. (ANRO)

Role
Chief Financial Officer
Signature
/s/ Erin R. McQuade, Attorney-in-Fact
Stock symbol
ANRO
Transactions as of
Feb 1, 2024
Transactions value $
$0
Form type
3
Date filed
2/1/2024, 06:48 PM
Next filing
Feb 7, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ANRO Employee Stock Option (Right to Buy) Feb 1, 2024 Common Stock 112K $2.32 Direct F1
holding ANRO Employee Stock Option (Right to Buy) Feb 1, 2024 Common Stock 22.5K $2.32 Direct F2
holding ANRO Employee Stock Option (Right to Buy) Feb 1, 2024 Common Stock 45K $6.23 Direct F3
holding ANRO Employee Stock Option (Right to Buy) Feb 1, 2024 Common Stock 33.8K $6.23 Direct F4
holding ANRO Employee Stock Option (Right to Buy) Feb 1, 2024 Common Stock 202K $5.30 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option vested on September 8, 2022, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F2 The shares subject to the option are fully vested and exercisable.
F3 One forty-eighth (1/48th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of September 21, 2022, subject to the Reporting Person's continuous service through such vesting date.
F4 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F5 One-third (1/3rd) of the shares underlying the option shall vest upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option shall vest over a period of four years, with 25% of the shares underlying the time-based portion vesting on December 20, 2024, and 1/48 of the shares underlying the time-based portion vesting on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date.